In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At APA, Neuronetics Launches TMS

Executive Summary

For millions of Americans who suffer from moderate to severe depression-and millions more around the world-existing drug therapies don't provide adequate treatment. For some, the drugs simply don't work; for others, the drugs treat their depression, but their side effects are so debilitating that the cure is worse than the disease. Now, Neuronetics says it has a new approach to depression treatment, one based on the focused delivery of magnetic energy, that works for these otherwise untreatable patients. More importantly, the company claims, it now has the data to prove it.

You may also be interested in...



Neuronetics Inc.

Neuronetics Inc. has developed a device for treating serious depression in pharmaco-resistant patients. The company believes that its repetitive Transcranial Magnetic Stimulation technology, delivered noninvasively in an outpatient setting, is free of the serious side effects that accompany antidepressant drugs; moreover that it will be more effective and much safer for patients than the only currently approved neuromodulation technology for depression: electroconvulsive therapy.

QUOTED. 8 August 2020. Ashley Wittorf.

AdvaMed Accell executive director Ashley Wittorf spoke in support of a proposed US House bill that would give financial help to small companies making products to address COVID-19.

Roche’s Evrysdi Approved For SMA, Priced Below Competitors

Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL043097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel